Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through mergers and acquisitions
Powered by Gab AI
The Story At A Glance
Reading this article now — analysis appears below
💡 AI analysis provides alternative perspectives on current events
Recent stories from across the outlets Alto indexes.
From this story — each link opens a live data page or a tool already filled in.
All toolsAll topicsSource directoryStory timelinesHeadline comparisonSearchMost read
Official merchandise. Every order funds free speech infrastructure.
Add Alto to your home screen for breaking news — no app store, no account.
Compare notes on treatments, studies, and outcomes without a warning label pasted over the thread.
We're not just another social network. We're a platform built on principles that matter.
All First Amendment protected speech is welcome. No algorithmic throttling or shadow banning.
We maintain a clean environment. Explicit adult content is strictly prohibited.
Third-world IPs are blocked. No scammers, no spam farms. Built for Western civilization.
Our users are our investors and customers. You're not the product being sold.
A decade of standing strong. Banned from app stores, banks—and still here.
We reject foreign censorship demands. Built by Americans, for free people.
Alto is funded entirely by readers like you. Your donation helps us continue delivering curated news from a right-wing Christian Nationalist perspective, powered by Gab AI.